|

Phesgo Clinical Trials

3 actively recruiting trials across 2 locations

Also known as: RG6264, RO7198574, pertuzumab plus trastuzumab plus hyaluronidase-zzxf

Pipeline

Phase 2: 2Phase 3: 1

Top Sponsors

  • Hoffmann-La Roche1
  • GBG Forschungs GmbH1
  • Dana-Farber Cancer Institute1

Indications

  • Breast Cancer3
  • Cancer3
  • HER2-positive Breast Cancer2
  • Stage IV Breast Cancer1
  • Estrogen Receptor-positive Breast Cancer1

Other1 trial

Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer
Phase 2

Gilbert, Arizona1 trial

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Banner Health MD Anderson AZ

Phase 3

Boston, Massachusetts1 trial

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Dana-Farber Cancer Institute

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.